Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro

Abstract

This study was designed to determine the impact of chrysoeriol on proliferation and cell cycle progression in the human multiple myeloma cell lines RPMI 8226 and KM3, and its related molecular mechanisms. Chryseoriol was identified by using the phosphorylated AKT-specific cytoblot high throughput assay. CCK-8 assay was employed to examine the growth inhibition rate and IC₅₀ (48 h) in peripheral blood mononuclear cells (PBMNCs), RPMI 8226 and KM3 cells treated with chrysoeriol at various concentrations. Cells were labeled with 5–6-carboxyfluorescein diacetate succinimidyl ester (CFSE), and the proliferation dynamics was detected by flow cytometry and analyzed with ModFit software. The cell cycles of RPMI 8226 and KM3 cells were measured by flow cytometry when the IC₅₀ concentration of chrysoeriol was adopted. The alterations in cell-cycle related proteins (Cyclin B1, Cyclin D1, p21) and proteins in PI3K-AKT-mTOR pathway were determined by Western blot analysis. The results showed the proliferation of multiple myeloma cells was significantly inhibited by chrysoeriol, resulting in cell cycle arrest in G₂/M phase. Chrysoeriol could significantly reduce the expression of p-AKT (s473) and p-4eBP1 (t37/46) protein, meanwhile enhanced Cyclin B1 and p21 protein expression. Similar effects were not observed in PBMNCs from normal donors. It was concluded that chrysoeriol was a selective PI3K-AKT-mTOR pathway inhibitor. It restrained the proliferation of human multiple myeloma cells, but didn’t affect proliferation of PBMNCs from normal donors. It might exhibit the cell cycle regulatory effect via the inhibition of PI3K-AKT-mTOR signal pathway.

Keywords

chrysoeriol / multiple myeloma / proliferation inhibition / G₂/M arrest / PI3K-AKT-mTOR signal pathway

References

[1] JacintoE., LoewithR., SchmidtA., et al.. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol, 2004, 6(11): 1122-1128

[2] SarbassovD.D., GuertinD.A., AliS.M., et al.. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307(5712): 1098-1101

[3] DukeJ.A., BogenschutzM.J., DuC.J., et al.. . Handbook of Medicinal Herbs, 20022nd ed.USA, CRC Press, 612-613

[4] SchinellaG.R., GinerR.M., RecioM.C., et al.. Anti-inflammatory effects of South American Tanacetum vulgare. J Pharm Pharmacol, 1998, 50(9): 1069-1074

[5] HanL.K., SumiyoshiM., ZhengY.N., et al.. Anti-obesity action of Salix matsudana leaves (Part 2). Isolation of anti-obesity effectors from polyphenol fractions of Salix matsudana. Phytother Res, 2003, 17(10): 1195-1198

[6] KimJ.H., ChoY.H., ParkS.M., et al.. Antioxidants and inhibitor of matrix metalloproteinase-1 expression from leaves of Zostera marina L. Arch Pharm Res, 2004, 27(2): 177-183

[7] ChoiD.Y., LeeJ.Y., KimM.R., et al.. Chrysoeriol potently inhibits the induction of nitric oxide synthase by blocking AP-1 activation. J Biomed Sci, 2005, 12(6): 949-959

[8] SnijmanP.W., SwanevelderS., JoubertE., et al.. The antimutagenic activity of the major flavonoids of rooibos (Aspalathus linearis): some dose-response effects on mutagen activation-flavonoid interactions. Mutat Res, 2007, 631(2): 111-123

[9] TakemuraH., UchiyamaH., OhuraT., et al.. A methoxyflavonoid, chrysoeriol, selectively inhibits the formation of a carcinogenic estrogen metabolite in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol, 2010, 118(1–2): 70-76

[10] SeidlS., KaufmannH., DrachJ., et al.. New insights into the pathophysiology of multiple myeloma. Lancet Oncol, 2003, 4(9): 557-564

[11] YangJ., ShamjiA., MatchacheepS., et al.. Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem Biol, 2007, 14(4): 371-377

[12] ChunK.H., KosmederJ.W.2nd, SunS., et al.. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst, 2003, 95(4): 291-302

[13] CullyM., YouH., LevineA.J., et al.. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer, 2006, 6(3): 184-192

[14] HayN.. The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 2005, 8(3): 179-183

[15] GrunwaldV., DeGraffenriedL., RusselD., et al.. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res, 2002, 62(21): 6141-6145

[16] MemmottR.M., DennisP.A.. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal, 2009, 21(5): 656-664

[17] StrimpakosA.S., KarapanagiotouE.M., SaifM.W., et al.. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev, 2009, 35(2): 148-159

[18] ChaB.Y., ShiW.L., YonezawaT., et al.. An inhibitory effect of chrysoeriol on platelet-derived growth factor (PDGF)-induced proliferation and PDGF receptor signaling in human aortic smooth muscle cells. J Pharmacol Sci, 2009, 110(1): 105-110

[19] WendelH.G., De StanchinaE., FridmanJ.S., et al.. Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 2004, 428(6980): 332-337

[20] Garcia EcheverriaC., SellersW.R.. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene, 2008, 27(41): 5511-5526

[21] NasmythK.. Viewpoint: putting the cell cycle in order. Science, 1996, 274(5293): 1643-1645

[22] CappellettiV., FioravantiL., MiodiniP., et al.. Genistein blocks breast cancer cells in the G (2) M phase of the cell cycle. J Cell Biochem, 2000, 79(4): 594-600

[23] BjornstiM.A., HoughtonP.J.. The TOR pathway: a target for cancer therapy. Nat Rev Cancer, 2004, 4(5): 335-348

[24] HoefferC.A., KlannE.. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci, 2010, 33(2): 67-75

This project was supported by grants from the National Natural Sciences Foundation of China (No. 30770914; No. 30901587) and China State Key Basic Research Program (No. 2002CB513100).